AstraZeneca dumps phase 3 renal cell carcinoma program

AstraZeneca has scrapped development of savolitinib as a monotherapy treatment for papillary renal cell carcinoma. The phase 3 program was one of five projects removed from AstraZeneca’s pipeline in conjunction with its second-quarter results.